Yıl: 2018 Cilt: 5 Sayı: 1 özel Sayfa Aralığı: 12 - 16 Metin Dili: İngilizce DOI: 10.4274/jpr.87609 İndeks Tarihi: 02-08-2019

An Evalution of the Demographic and Clinical Characterictics of Patients with GM2 Gangliosidosis

Öz:
Aim: The purpose of our study is to submit the demographic, phenotypic and age at diagnosis characteristics of children with GM2 gangliosidosis.Materials and Methods: Patients with GM2 gangliosidosis who were referred to Ege University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Nutritionand Metabolism between January 2004 and December 2016, were included in this study. Diagnosis was confirmed by determining the level of serum β-hexosaminidaseactivity and genetic mutation analysis. The demographic and clinical features are reported for 8 patients with Tay-Sachs disease (TSD) and 6 with Sandhoff disease.Results: The mean age at diagnosis was 18.2 months (range 4-48 months) and 14.5 months (range 8-36 months) for patients with TSD or Sandhoff disease respectively. Theinitial and main complaint in 100% of the patients were neurological disorders, such as developmental delay, developmental regression or both; seizures and macrocephaly.None of the patients exhibited evidence of organomegaly. Cranial magnetic resonance imaging results were normal in 36% of the cases, 55% of the cases had bilateral thalamiinvolvement presenting as T2 hyperintensity especially at the posterior thalami and 9% of cases had myelination delay.Conclusion: GM2 gangliosidosis disease should be considered for children with developmental regression and/or delay. To prevent a delay in diagnosis, β-hexosaminidaseactivity in serum and genetic mutation analysis should be undertaken in suspected cases. Curative gene therapy may be available in the future.
Anahtar Kelime:

Konular: Pediatri
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • Meikle PJ, Hopwood JJ, Clague AE, et al. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54.
  • Andermann E, Scriver CR, Wolfe LS, et al. Genetic variants of Tay-Sachs disease: Tay-Sachs disease and Sandhoff’s disease in French Canadians, juvenile Tay-Sachs disease in Lebanese Canadians, and a Tay-Sachs screening program in the French- Canadian population. Prog Clin Biol Res 1977;18:161-88.
  • Myrianthopoulos N. Some Epidemiological and Genetic Aspects of Tay Sachs Disease. (Academic Press, New York, 1962.).
  • Sandhoff K. The GM2-gangliosidoses and the elucidation of the beta-hexosaminidase system. Adv Genet 2001;44:67-91.
  • Gravel RA, Triggs-Raine BL, Mahuran DJ. Biochemistry and genetics of Tay-Sachs disease. Can J Neurol Sci 1991;18:419-23.
  • Martino S, Cavalieri C, Emiliani C, et al. Restoration of theGM2 ganglioside metabolism in bone marrow derived stromal cells from Tay-Sachs disease animal model. Neurochem Res 2002;27:793-800.
  • Martino S, Emiliani C, Tancini B, et al. Absence of metabolic cross-correction in Tay-Sachs cells:implications for gene therapy. J Biol Chem 2002;277:20177-84.
  • Gravel R, Kaback M, Proia R, et al. The GM2 gangliosidosis. In: Scriver CR, Beaudet A, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of İnherited Disease. 8. New York: McGraw-Hill 2001;3827-76.
  • Sandhoff K, Andreae U, Jatzkewitz H. Deficient hexozaminidase activity in an exceptional case of Tay– Sachs disease with additional storage of kidney globoside in visceral organs. Life Sci 1968;7:283-8.
  • Krivit W, Desnick RJ, Lee J, et al. Generalized accumulation of neutral glycosphingolipids with GM2 ganglioside accumulation in the brain. Sandhoff disease [variant of Tay– Sachs disease]. Am J Med 1972;52:763-70.
  • ohnsonWG. The clinical spectrum of hexosaminidase deficiency disease. Neurology 1981;31:1453-6.
  • Maegawa G, Stockley T, Tropak M, et al. The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported. Pediatrics 2006;118:e1550-62. 13. Neudorfer O, Pastores GM, Zeng BJ, Gianutsos J, Zaroff CM, Kolodney EH. Late-onset Tay–Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients. Genet Med 2005;7:119-23.
  • Federico A, Palmeri S, Malandrini A, Fabrizi G, Mondelli M, Guazzi GC. The clinical aspects of adult hexosaminidase deficiencies. Dev Neurosci 1991;13:280-7.
  • Gravel RA, Kaback MM, Proia RL, Sandhoff K, Suzuki K, Suzuki K. The GM2 gangliosidoses. In: Valle D, Beaudet AL, Vogelstein B, Kinsler KW, Antonarakis SE, Ballabio A, editors. The Online Metabolic & Molecular Bases of Inherited Disease. Scriver’s OMMBID. New York: McGraw-Hill, 2010: http://dx.doi.org/10.1036/ommbid.184.
  • Gort L, de Olano N, Macías-Vidal J, Coll MA; Spanish GM2 Working Group. GM2 gangliosidoses in Spain: analysis of the HEXA and HEXB genes in 34 Tay-Sachs and 14 Sandhoff patients. Gene 2012 Sep 10;506:25-30. Epub 2012 Jul 10
  • Karimzadeh P, Jafari N, Nejad Biglari H, et al. GM2- gangliosidosis (Sandhoff and Tay Sachs disease): Diagnosis and neuroimaging findings (an Iranian pediatric case series). Iran J Child Neurol 2014;8:55-60.
  • Kokot W, Raczyńska K, Krajka-Lauer J, Iwaszkiewicz- Bilikiewicz B, Wierzba J. Sandhoff’s and Tay-Sachs disease-- based on our own cases. Klin Oczna 2004;106(3 Suppl):534- 6.
  • Barness LA, Henry K, Kling P, et al. A 7-year old white-male boy withprogressive neurological deterioration. Am J Med Genet 1991;40:271-9.
  • Yun YM, Lee SN. A case refort of Sandhoff disease. Korean J Ophthalmol 2005;19:68-72.
  • Smith NJ, Winstone AM, Stellitano L, Cox TM, Verity CM. GM2 gangliosidosis in a UK study of children with progressive neurodegeneration: 73 cases reviewed. Dev Med Child Neurol 2012;54:176-82.
APA Er E, Canda E, Yazıcı H, ERASLAN C, Y. Sozmen E, KALKAN UÇAR S, Çoker M (2018). An Evalution of the Demographic and Clinical Characterictics of Patients with GM2 Gangliosidosis. , 12 - 16. 10.4274/jpr.87609
Chicago Er Esra,Canda Ebru,Yazıcı Havva,ERASLAN CENK,Y. Sozmen Eser,KALKAN UÇAR Sema,Çoker Mahmut An Evalution of the Demographic and Clinical Characterictics of Patients with GM2 Gangliosidosis. (2018): 12 - 16. 10.4274/jpr.87609
MLA Er Esra,Canda Ebru,Yazıcı Havva,ERASLAN CENK,Y. Sozmen Eser,KALKAN UÇAR Sema,Çoker Mahmut An Evalution of the Demographic and Clinical Characterictics of Patients with GM2 Gangliosidosis. , 2018, ss.12 - 16. 10.4274/jpr.87609
AMA Er E,Canda E,Yazıcı H,ERASLAN C,Y. Sozmen E,KALKAN UÇAR S,Çoker M An Evalution of the Demographic and Clinical Characterictics of Patients with GM2 Gangliosidosis. . 2018; 12 - 16. 10.4274/jpr.87609
Vancouver Er E,Canda E,Yazıcı H,ERASLAN C,Y. Sozmen E,KALKAN UÇAR S,Çoker M An Evalution of the Demographic and Clinical Characterictics of Patients with GM2 Gangliosidosis. . 2018; 12 - 16. 10.4274/jpr.87609
IEEE Er E,Canda E,Yazıcı H,ERASLAN C,Y. Sozmen E,KALKAN UÇAR S,Çoker M "An Evalution of the Demographic and Clinical Characterictics of Patients with GM2 Gangliosidosis." , ss.12 - 16, 2018. 10.4274/jpr.87609
ISNAD Er, Esra vd. "An Evalution of the Demographic and Clinical Characterictics of Patients with GM2 Gangliosidosis". (2018), 12-16. https://doi.org/10.4274/jpr.87609
APA Er E, Canda E, Yazıcı H, ERASLAN C, Y. Sozmen E, KALKAN UÇAR S, Çoker M (2018). An Evalution of the Demographic and Clinical Characterictics of Patients with GM2 Gangliosidosis. The Journal of Pediatric Research, 5(1 özel), 12 - 16. 10.4274/jpr.87609
Chicago Er Esra,Canda Ebru,Yazıcı Havva,ERASLAN CENK,Y. Sozmen Eser,KALKAN UÇAR Sema,Çoker Mahmut An Evalution of the Demographic and Clinical Characterictics of Patients with GM2 Gangliosidosis. The Journal of Pediatric Research 5, no.1 özel (2018): 12 - 16. 10.4274/jpr.87609
MLA Er Esra,Canda Ebru,Yazıcı Havva,ERASLAN CENK,Y. Sozmen Eser,KALKAN UÇAR Sema,Çoker Mahmut An Evalution of the Demographic and Clinical Characterictics of Patients with GM2 Gangliosidosis. The Journal of Pediatric Research, vol.5, no.1 özel, 2018, ss.12 - 16. 10.4274/jpr.87609
AMA Er E,Canda E,Yazıcı H,ERASLAN C,Y. Sozmen E,KALKAN UÇAR S,Çoker M An Evalution of the Demographic and Clinical Characterictics of Patients with GM2 Gangliosidosis. The Journal of Pediatric Research. 2018; 5(1 özel): 12 - 16. 10.4274/jpr.87609
Vancouver Er E,Canda E,Yazıcı H,ERASLAN C,Y. Sozmen E,KALKAN UÇAR S,Çoker M An Evalution of the Demographic and Clinical Characterictics of Patients with GM2 Gangliosidosis. The Journal of Pediatric Research. 2018; 5(1 özel): 12 - 16. 10.4274/jpr.87609
IEEE Er E,Canda E,Yazıcı H,ERASLAN C,Y. Sozmen E,KALKAN UÇAR S,Çoker M "An Evalution of the Demographic and Clinical Characterictics of Patients with GM2 Gangliosidosis." The Journal of Pediatric Research, 5, ss.12 - 16, 2018. 10.4274/jpr.87609
ISNAD Er, Esra vd. "An Evalution of the Demographic and Clinical Characterictics of Patients with GM2 Gangliosidosis". The Journal of Pediatric Research 5/1 özel (2018), 12-16. https://doi.org/10.4274/jpr.87609